

Four New Lariciresinol-Based Lignan Glycosides from the Roots of *Rhus javanica* var. *roxburghiana*

by Ming-An Ouyang^a), Yung-Shung Wein^a), and Yueh-Hsiung Kuo^{*a)b)c)d)}

^a) Department of Chemistry, National Taiwan University, Taipei, Taiwan
(phone: +886-2-33661671; fax: +886-2-23636359; e-mail: yhkueo@ntu.edu.tw)

^b) Agricultural Biotechnology Research Center, Academia Sinica, Taipei, Taiwan




^c) College of Pharmacy, China Medical University, Taichung, Taiwan

^d) Research Center of Food and Biomolecules, National Taiwan University, Taipei, Taiwan

The four new lariciresinol-based lignan glycosides, (–)-lariciresinol 4'-(6''-*O*-feruloyl- β -D-glucopyranoside) (**1**), (–)-lariciresinol 4'-(4'',6''-di-*O*-feruloyl- β -D-glucopyranoside) (**2**), 5,5'-dimethoxylariciresinol 4'-(4'',6''-di-*O*-feruloyl)- β -D-glucopyranoside (**3**), and 4-*O*-[α -(1,2-dihydroxyethyl)syringyl]-5,5'-dimethoxylariciresinol 4'-(4'',6''-di-*O*-feruloyl- β -D-glucopyranoside) (**4**), together with two known ones, lariciresinol 4'- β -D-glucopyranoside (**5**) and tortoside B (**6**), were isolated from the BuOH extract of *Rhus javanica* var. *roxburghiana* roots, and their structures were established by means of various spectroscopic techniques.

Introduction. – The plants of Anacardiaceae are widespread in the tropical and subtropical area. Some of them are poisonous plants and lead to allergic reaction, such as *Toxicodendron radicans* and *Mangifera indica*, a tropical Asian evergreen tree cultivated for its edible fruit. Five *Rhus* plants are found in the island of Taiwan. They are *R. ambigua*, *R. hypoleuca*, *R. javanica* var. *roxburghiana* (= *R. semialata*), *R. succedanea*, and *R. sylvestris*. Previous investigations on the chemical constituents of *R. javanica* have resulted in the isolation of steroids, triterpenes, flavanoids, aromatics, and condensed tannins [1–7]. The root of this plant is used as a folk herb for the treatment of diarrhea, spermatorrhea, and malaria [8]. Kuo *et al.* have isolated 6-pentadecylsallylic acid as an antithrombin component [3]. For the purpose of understanding the unusual secondary metabolism in *Rhus* plants and elucidating the pharmacologically active constituents of traditional Chinese medicines derived from *Rhus* plants, we initiated studies of the chemical constituents of the root of *R. javanica*. From the AcOEt-soluble fraction of the MeOH extract, we have isolated and purified 37 known compounds, two of them exhibiting significant cytotoxic activity [9]. This paper deals with the structural elucidation of the four new lariciresinol-based lignan glycosides **1–4** along with lariciresinol 4'-(β -D-glucoside) (**5**) [10] and tortoside B (**6**) [11], isolated from the BuOH-soluble fraction of the MeOH extract of the root of *R. javanica* ((–)-lariciresinol = (2*S*,3*R*,4*R*)-tetrahydro-2-(4-hydroxy-3-methoxyphenyl)-4-[(4-hydroxy-3-methoxyphenyl)methyl]furan-3-methanol¹⁾).

¹⁾ Trivial or arbitrary atom numbering; for systematic names, see the *Exper. Part.*



Results and Discussion. – Compound **1** revealed an $[M + 1]^+$ peak at m/z 699 in the FAB-MS. The HR-FAB-MS spectrum suggested the molecular formula $C_{36}H_{42}O_{14}$. The IR spectrum showed absorptions of a conjugated-ester carbonyl group (1699 cm^{-1}) and aromatic rings (1600 cm^{-1}). Basic hydrolysis of **1** afforded two products, ferulic acid (= (2*E*)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic acid; **S¹-OH**) and a glucoside which was identified as lariciresinol 4'-(β -D-glucoside) (**5**) [10]. The ^1H - and ^{13}C -NMR (Table 1), COSY, HMQC, HMBC, and NOESY data allowed to identify **1** as (–)-lariciresinol 4'-(6''-*O*-feruloyl- β -D-glucopyranoside).

The DEPT experiment established the presence of 3 MeO, 4 CH_2 , and 19 CH groups and of 10 quaternary C-atoms in **1**. The ^1H -NMR and $^1\text{H}, ^1\text{H}$ -COSY data showed the presence of three *ABX* patterns in the aromatic region, *trans* double-bond protons at δ 7.61 (*d*, $J = 16.0\text{ Hz}$, 1 H) and 6.32 (*d*, $J = 16.0\text{ Hz}$, 1 H), and a sugar anomeric proton at δ 4.90 (*d*, $J = 7.2\text{ Hz}$). The ^1H -NMR data of **1** and its aglycone disclosed a diarylepoxy lignan skeleton characterized by the presence of one downfield-shifted benzylic CH signal at δ 4.75 (*d*, $J = 6.0\text{ Hz}$, H–C(7)), benzylic CH_2 signals at δ 2.88 (*dd*, $J = 13.4, 4.5\text{ Hz}$, H_a –C(7')) and 2.46 (*dd*, $J = 13.4, 4.8\text{ Hz}$, H_b –C(7')), and CH_2OH signals (δ 3.81 and 3.64, each 1 H, overlapping with other singlets). Such an NMR pattern along with two sets of *ABX* system signals of aromatic protons and two MeO signals suggested that the aglycone should be lariciresinol [10]. The NOESY experiment confirmed that H–C(8) and H–C(8') are in *cis*-configuration. Only one phenolic proton at δ 8.50 was observed, the other phenolic position of the lariciresinol part was considered to be linked to a glucose moiety. The HMQC and HMBC exhibited the following key correlations: H–C(7) (δ 4.75)/C(1), C(2), C(6), C(8), C(9), C(8'), and C(9'), H–C(7') (δ 2.88)/C(1'), C(2'), C(6'), C(8'), and C(9'), H–C(1'') (δ 4.90)/C(4') and C(2''). The more deshielded proton of $\text{CH}_2(6')$ ($\delta(\text{H})$ 4.35 and 4.51)

Table 1. ^{13}C - and ^1H -NMR Data (400 and 100 MHz) of Compounds **1** and **2**¹. δ in ppm, J in Hz.

	1 ((D ₆)acetone)		2 (CD ₃ OD)	
	$\delta(\text{C})$	$\delta(\text{H})$	$\delta(\text{C})$	$\delta(\text{H})$
C(1)	139.7		139.2	
H–C(2)	112.9	6.79 (<i>d</i> , $J=2.4$)	112.9	6.86 (<i>d</i> , $J=2.1$)
C(3)	146.5		150.7	
C(4)	149.9		146.3	
H–C(5)	117.5	7.12 (<i>d</i> , $J=8.0$)	117.9	6.77 (<i>d</i> , $J=8.4$)
H–C(6)	118.7	6.76 (<i>dd</i> , $J=8.0, 2.4$)	119.2	7.04 (<i>dd</i> , $J=8.4, 2.1$)
H–C(7)	82.9	4.75 (<i>d</i> , $J=6.0$)	83.3	4.70 (<i>d</i> , $J=6.8$)
H–C(8)	53.8	2.22–2.29 (<i>m</i>)	53.6	2.22–2.28 (<i>m</i>)
CH ₂ (9)	60.3	3.81 ^a), 3.64 ^a)	60.3	3.87 ^a), 3.59 ^a)
MeO–C(3)	56.2	3.79 (<i>s</i>)	56.8	3.77 (<i>s</i>)
C(1')	133.1		133.0	
H–C(2')	111.1	6.96 (<i>d</i> , $J=2.0$)	110.9	6.89 (<i>d</i> , $J=2.0$)
C(3')	148.0		148.4	
C(4')	145.4		145.1	
H–C(5')	115.6	6.72 (<i>d</i> , $J=8.0$)	115.8	6.78 (<i>d</i> , $J=8.0$)
H–C(6')	121.6	6.32 (<i>dd</i> , $J=8.0, 2.0$)	121.8	6.58 (<i>dd</i> , $J=8.0, 2.0$)
CH ₂ (7')	33.5	2.88 (<i>dd</i> , $J=13.4, 4.5$), 2.46 (<i>dd</i> , $J=13.4, 4.8$)	33.5	2.82 (<i>dd</i> , $J=13.6, 4.4$), 2.40 (<i>dd</i> , $J=13.6, 4.9$)
H–C(8')	43.3	2.61 (<i>m</i>)	43.4	2.61 (<i>m</i>)
CH ₂ (9')	73.1	3.85 ^a), 3.81 ^a)	73.5	3.92 ^a), 3.57 ^a)
MeO–C(3')	56.3	3.79 (<i>s</i>)	56.7	3.79 (<i>s</i>)
H–C(1'')	102.5	4.90 (<i>d</i> , $J=7.2$)	102.6	4.90 (<i>d</i> , $J=7.8$)
H–C(2'')	74.6	3.53 ^a)	74.2	3.55 ^a)
H–C(3'')	77.7	3.59 ^a)	75.1	3.70 ^a)
H–C(4'')	71.2	3.48 ^a)	72.5	5.06 (<i>t</i> , $J=9.6$)
H–C(5'')	75.0	3.73 ^a)	72.9	3.82 ^a)
CH ₂ (6'')	64.1	4.51 (<i>dd</i> , $J=12.4, 2.0$), 4.35 (<i>dd</i> , $J=12.4, 6.8$)	64.1	4.33 (<i>dd</i> , $J=12.0, 6.0$), 4.24 (<i>dd</i> , $J=12.0, 5.0$)
C(1''')	127.2		126.8	
H–C(2''')	111.0	7.33 (<i>d</i> , $J=2.4$)	111.2	7.09 (<i>d</i> , $J=2.0$)
C(3''')	148.6		148.9	
C(4''')	149.9		150.3	
H–C(5''')	116.0	6.87 (<i>d</i> , $J=7.6$)	116.3	6.78 (<i>d</i> , $J=8.0$)
H–C(6''')	124.0	7.13 (<i>dd</i> , $J=7.6, 2.4$)	124.0	7.00 (<i>dd</i> , $J=8.0, 2.0$)
H–C(7''')	145.8	7.61 (<i>d</i> , $J=16.0$)	147.5	7.56 (<i>d</i> , $J=16.0$)
H–C(8''')	115.4	6.32 (<i>d</i> , $J=16.0$)	115.8	6.33 (<i>d</i> , $J=16.0$)
C(9''')	167.2		168.2	
MeO–C(3''')	56.4	3.90 (<i>s</i>)	56.4	3.84 (<i>s</i>)
C(1''''')			126.7	
H–C(2''''')			111.1	7.07 (<i>d</i> , $J=2.0$)
C(3''''')			148.9	
C(4''''')			150.3	
H–C(5''''')			116.3	6.78 (<i>d</i> , $J=8.0$)
H–C(6''''')			124.0	7.00 (<i>dd</i> , $J=8.0, 2.0$)
H–C(7''''')			146.9	7.62 (<i>d</i> , $J=16.0$)
H–C(8''''')			115.7	6.22 (<i>d</i> , $J=16.0$)
C(9''''')			168.0	
MeO–C(3''''')			56.3	3.84 (<i>s</i>)

^a) Overlapping with other signals.

showed a HMBC correlation with C(9''), the carbonyl group of the ester, that confirmed that the feruloyl moiety is linked to C(6'').

Compound **2** had the molecular formula C₄₆H₅₀O₁₇ according to the exact molecular ion in the HR-FAB-MS and the ¹³C-NMR spectra (Table 1). The IR absorptions were assignable to conjugated ester carbonyl groups (1699 cm⁻¹), C=C bonds (1633 cm⁻¹), and aromatic rings (1597 and 1522 cm⁻¹). Comparison of the NMR data (Table 1) of compounds **1** and **2** revealed a closely similar aglycone and sugar moiety, the only difference being the presence of an additional feruloyl moiety in **2**. The structure of **2** was determined to be (-)-lariciresinol 4'-(4'',6''-di-*O*-feruloyl-β-D-glucopyranoside).

The ¹H NMR spectrum of **2** exhibited two sets of *trans* double-bond protons at δ 7.56 (*d*, *J* = 16.0 Hz, 1 H) and 6.33 (*d*, *J* = 16.0 Hz, 1 H), and 7.62 (*d*, *J* = 16.0 Hz, 1 H) and 6.22 (*d*, *J* = 16.0 Hz, 1 H), four *ABX* systems of aromatic protons, an anomeric sugar proton at δ 4.90 (*d*, *J* = 7.8 Hz), a benzylic CH signal at δ 4.70 (*d*, *J* = 6.8 Hz), and benzylic CH₂ signals at δ 2.82 (*dd*, *J* = 13.6, 4.4 Hz, H_a-C(7')) and 2.40 (*dd*, *J* = 13.6, 4.9 Hz, H_b-C(7')). The following key HMBC correlations were observed: CH₂(6'') (δ 4.33 and 4.24)/C(9''), H-C(4'') (δ 5.06)/C(9''), H-C(7)/C(1), C(2), C(6), C(9), C(8'), and C(9'), H-C(7) (δ 2.82 and 2.40)/C(8), C(1'), C(2'), C(6'), C(8'), and C(9'), and H-C(1'')/C(4') (Fig. 1). The signal at δ 5.08 (*t*, *J* = 9.6 Hz) was assigned as H-C(4'') since it had a NOESY correlation with H-C(6''). The above evidence revealed that the sugar moiety is a glucose and the secondary feruloyl group is linked at C(4'').




Fig. 1. HMBC Correlations in Compound **2**

Compound **3** was obtained as colorless powder. Based on the HR-FAB-MS and ¹³C-NMR data (Table 2), compound **3** has the molecular formula C₄₈H₅₄O₁₉. The IR spectrum indicated the presence of OH (3422 cm⁻¹) and conjugated ester carbonyl groups (1708 cm⁻¹), of C=C bonds (1633 cm⁻¹), and of aromatic rings (1596 and 1501 cm⁻¹). On basic hydrolysis, **3** gave ferulic acid and tortoside B (**6**) [11]. The structure of **3** was elucidated as 5,5'-dimethoxyariciresinol 4'-(4'',6''-di-*O*-feruloyl-β-D-glucopyranoside).

The ¹H- and ¹³C-NMR spectra (Table 2) showed the presence of a β-D-glucopyranosyl moiety (δ(C) 105.4; δ 4.87 (*d*, *J* = 7.6 Hz)), two tetrasubstituted symmetrical benzene rings, two feruloyl ester moieties, three CH₂ groups (δ(C) 34.3, 60.4, 73.0, the later two being oxygenated), and three CH groups (δ(C) 54.0, 83.3, and 43.2) along with four MeO signals (δ 3.82 (*s*, 6 H) and 3.79 (*s*, 6 H)). Comparison of the ¹H- and ¹³C-NMR spectra of **3** and tortoside B (**6**) [11] showed that they have a similar structure, except for two additional feruloyl moieties in **3**. The signal at δ 5.09 (*t*, *J* = 9.0 Hz) was assigned as H-C(4'') which exhibited a NOESY correlation with CH₂(6'') (δ 4.21 and 4.18). This evidence confirmed that the two feruloyl moieties were connected to C(6'') and C(4'').

The HR-FAB-MS of compound **4** had a pseudomolecular-ion peak $[M + H]^+$ at m/z 1161.4170 consistent with the molecular formula $C_{59}H_{68}O_{24}$. The IR spectrum indicated the presence of OH (3337 cm^{-1}) and conjugated ester carbonyl groups (1706 cm^{-1}), of C=C bonds (1632 cm^{-1}), and of aromatic rings (1600 and 1514 cm^{-1}), while the UV absorptions were similar to those of **3**. Comparison with the NMR data of **3** and **4** revealed a close resemblance of **3** and **4**; except for an additional syringylglyceryl-derived moiety in compound **4**. Compound **4** was elucidated as 4-*O*-[α -(1,2-dihydroxyethyl)syringyl]-5,5'-dimethoxyariciresinol 4'-(4'',6''-di-*O*-feruloyl- β -D-glucopyranoside).

The ^1H - and ^{13}C -NMR spectra of **4** showed the presence of a β -D-glucopyranosyl moiety, two feruloyl ester moieties, a 5,5'-dimethoxyariciresinol part, and a syringylglyceryl-derived unit with the signals $\delta(\text{H})$ 6.69 (s, H-C(2'''''), H-C(6''''')), $\delta(\text{C})$ 141.2 (C(1''''')), 104.7 (C(2''''')), 153.7 (C(3''''')), C(5''''')), and 132.6 (C(4''''')), two CH signals at $\delta(\text{H})$ 4.98 (d, $J = 6.2\text{ Hz}$, 1 H) and $\delta(\text{C})$ 87.8 (C(7''''')), and $\delta(\text{H})$ 4.16–4.21 (m, 1 H) and $\delta(\text{C})$ 73.0 (C(8''''')), CH₂ signals at $\delta(\text{H})$ 3.83 and 3.44 and $\delta(\text{C})$ 61.0 (C(9''''')), and two MeO signals at $\delta(\text{H})$ 3.84 (s, 6 H). The COSY experiment with **4** indicated the contiguous protons shown by bold lines in Fig. 2. The chemical shifts of H-C(7''''') and C(7''''') appeared downfield in **4** as compared to 'syringylglycerol' [12–14], establishing that H-C(7''''') was linked to a phenol OH group rather than to an alcohol OH group. The HMQC and HMBC experiments (Fig. 2) of **4** revealed the following correlations: CH₂(6'') (δ 4.23, 4.21)/C(9''') (δ 166.8), H-C(4'') (δ 5.08)/C(9''') (δ 166.7), H-C(1'') (δ 4.84)/C(4') (δ 134.3), and H-C(7''''') (δ 4.98)/C(4) (δ 135.6).




Fig. 2. HMBC and COSY Correlations in Compound **4**

Experimental Part

General. CC = Column chromatography. TLC: Merck TLC plates (silica gel 60 F_{254}), visualization by spraying with 5% (v/v) H_2SO_4 in EtOH. Optical rotations: Jasco DIP-180 digital polarimeter. UV Spectra: Hitachi S-3200; λ_{max} ($\log \epsilon$) in nm. IR Spectra: Perkin-Elmer 983G; in cm^{-1} . ^1H - and ^{13}C -NMR, DEPT, ^1H , ^1H -COSY, NOESY, TOCSY, HMQC, and HMBC: Varian Unity-Plus-400 instrument. FAB-MS: Jeol JMS-HX-110 instrument; in m/z (rel. %).

Plant Material. The roots of *R. javanica* var. *roxburghiana* were collected from the suburb of Penton, Taiwan, in 1998. A voucher specimen (No. 191230) was deposited in the Department of Botany, National Taiwan University.

Extraction and Isolation. The dry roots of *R. javanica* (8 kg) were extracted with MeOH for 2 weeks. The extract was concentrated, the residue (300 g) dissolved and suspended in H_2O (2.5 l) and partitioned with AcOEt (3×3 l), and then the aq. phase extracted with BuOH (3×3 l). The BuOH extract was concentrated and the residue (70 g) subjected to dry CC (silica gel (1.0 kg), $\text{CHCl}_3/\text{MeOH}/\text{H}_2\text{O}$

Table 2. ^{13}C - and ^1H -NMR Data (CD_3COCD_3 , 400 and 100 MHz) of Compounds **3** and **4**^a

	3		4	
	$\delta(\text{C})$	$\delta(\text{H})$	$\delta(\text{C})$	$\delta(\text{H})$
C(1)	135.3		135.2	
H–C(2,6)	104.1	6.64 (s)	103.7	6.72 (s)
C(3)	148.5		148.2	
C(4)	135.6		135.6	
H–C(7)	83.3	4.77 (d, $J=6.0$)	83.3	4.83 (d, $J=6.0$)
H–C(8)	54.0	2.35 (br. sept., $J=6.4$)	53.8	2.34 (br. sept., $J=6.4$)
$\text{CH}_2(9)$	60.4	3.69 ^a), 3.85 ^a)	60.5	3.46 ^a), 3.88 ^a)
MeO–C(3,5)	56.6	3.79 (s)	56.6	3.80 (s)
C(1')	138.7		138.6	
H–C(2',6')	107.3	6.58 (s)	107.3	6.58 (s)
C(3',5')	153.7		153.7	
C(4')	134.4		134.3	
$\text{CH}_2(7')$	34.3	2.95 (dd, $J=13.2, 4.8, \text{H}_a$), 2.52 (dd, $J=13.2, 11.2, \text{H}_b$)	34.2	2.95 ^a), 2.52 (dd, $J=13.2, 11.2, \text{H}_b$)
H–C(8')	43.2	2.72 (m)	43.2	2.72 (m)
$\text{CH}_2(9')$	73.0	3.96 (dd, $J=8.4, 6.8$), 3.67 ^a)	73.2	3.96 (dd, $J=8.4, 6.8$), 3.67 ^a)
MeO–C(3',5')	56.9	3.82 (s)	56.9	3.83 (s)
H–C(1'')	105.4	4.87 (d, $J=7.6$)	105.3	4.84 (d, $J=7.6$)
H–C(2'')	75.9	3.62 (t, $J=9.0$)	75.9	3.62 (t, $J=9.0$)
H–C(3'')	75.2	3.78 ^a)	75.1	3.78 ^a)
H–C(4'')	73.0	5.09 (t, $J=9.0$)	72.3	5.08 (t, $J=9.0$)
H–C(5'')	72.3	3.80 ^a)	73.5	3.80 ^a)
$\text{CH}_2(6'')$	63.9	4.18 (dd, $J=12.0, 4.0$), 4.21 (dd, $J=12.0, 6.6$)	63.9	4.21 (dd, $J=12.0, 4.0$), 4.23 (dd, $J=12.0, 6.4$)
C(1''')	127.2		127.1	
H–C(2''')	111.1	7.32 (d, $J=1.6$)	111.1	7.32 (d, $J=1.6$)
C(3''')	148.5		148.5	
C(4''')	150.0		150.0	
H–C(5''')	115.9	6.85 (d, $J=8.0$)	115.9	6.85 (d, $J=8.0$)
H–C(6''')	124.0	7.12 (dd, $J=8.0, 1.6$)	124.0	7.12 (dd, $J=8.0, 1.6$)
H–C(7''')	146.2	7.63 (d, $J=15.6$)	146.3	7.63 (d, $J=15.6$)
H–C(8''')	115.3	6.42 (d, $J=15.6$)	115.3	6.42 (d, $J=15.6$)
C(9''')	166.8		166.8	
MeO–C(3''')	56.3	3.85 (s)	56.3	3.89 (s)
C(1''''')	127.2		127.1	
H–C(2''''')	111.1	7.26 (d, $J=2.0$)	111.1	7.26 (d, $J=2.0$)
C(3''''')	148.5		148.5	
C(4''''')	149.9		149.9	
H–C(5''''')	115.9	7.05 (dd, $J=8.4, 2.0$)	115.9	7.05 (dd, $J=8.4, 2.0$)
H–C(6''''')	123.9	6.82 (d, $J=8.4$)	123.9	6.82 (d, $J=8.4$)
H–C(7''''')	145.8	7.55 (d, $J=15.6$)	145.8	7.55 (d, $J=15.6$)
H–C(8''''')	115.2	6.32 (d, $J=15.6$)	115.2	6.32 (d, $J=15.6$)
C(9''''')	166.7		166.7	
MeO–C(3''''')	56.3	3.86 (s)	56.3	3.87 (s)
C(1''''''')			141.2	
H–C(2''''''',6''''''')			104.7	6.69 (s)
C(3''''''',5''''''')			153.7	

Table 2 (cont.)

	3		4	
	$\delta(\text{C})$	$\delta(\text{H})$	$\delta(\text{C})$	$\delta(\text{H})$
C(4''''')			132.6	
H–C(7''''')			87.8	4.98 (<i>d</i> , <i>J</i> = 6.2)
H–C(8''''')			73.0	4.16–4.24 (<i>m</i>)
CH ₂ (9''''')			61.0	3.83 ^a), 3.44 ^a)
MeO–C(3''''', 5''''')			56.5	3.84 (<i>s</i>)

^a) Overlapping with other signals.

10:2:0.2): 13 fractions. Each fraction was subjected to *Sephadex LH-20* and *PR-18* (10 → 90% MeOH/H₂O) and finally, purified by CC (silica gel, CH₂Cl₂/AcOEt/MeOH 10:10:1 and CHCl₃/MeOH/H₂O 10:2:0.2): **1** (18 mg), **2** (30 mg), **3** (58 mg), **4** (21 mg), **5** (17 mg), and **6** (34 mg).

(–)-*Lariciresinol 4'-(6''-O-Feruloyl-β-D-glucopyranoside) (=2-Methoxy-4-[(3R,4R,5S)-tetrahydro-5-(4-hydroxy-3-methoxyphenyl)-4-(hydroxymethyl)furan-3-yl]methyl]phenyl β-D-Glucopyranoside 6-[(2E)-3-(4-Hydroxy-3-methoxyphenyl)prop-2-enoate]; **1**): White powder. $[\alpha]_{\text{D}}^{27} = -30.8$ (*c* = 0.21, acetone). UV (MeOH): 227 (4.16), 232 (4.01), 276 (4.00), 301 (sh), 330 (4.08). IR (KBr): 3370, 1699, 1600, 1514, 1461. ¹H- and ¹³C-NMR: see Table 1. FAB-MS: 699 (0.5, $[M + 1]^+$), 613 (1.5), 515 (3.7), 460 (4.0), 391 (42.5), 307 (100), 289 (56). HR-FAB-MS: 699.2659 ($[M + 1]^+$, C₃₆H₄₃O₁₄⁺; calc. 699.2652).*

(–)-*Lariciresinol 4'-(4'',6''-Di-O-feruloyl-β-D-glucopyranoside) (=2-Methoxy-4-[(3R,4R,5S)-tetrahydro-5-(4-hydroxy-3-methoxyphenyl)-4-(hydroxymethyl)furan-3-yl]methyl]phenyl β-D-Glucopyranoside 4,6-Bis[(2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate]; **2**): White powder. $[\alpha]_{\text{D}}^{27} = -21.4$ (*c* = 0.20, acetone). UV (MeOH): 227 (4.34), 233 (4.07), 278 (sh), 300 (4.01), 331 (4.11). IR (KBr): 3383, 1699, 1633, 1597, 1520. ¹H- and ¹³C-NMR: see Table 1. FAB-MS: 875 (0.3, $[M + 1]^+$), 615 (1.0), 515 (2.7), 460 (5.0), 391 (2.5), 307 (100), 289 (60). HR-FAB-MS: 875.3131 ($[M + 1]^+$, C₆₄H₅₁O₁₇⁺; calc. 857.3125).*

*5,5'-Dimethoxylariciresinol 4'-(4'',6''-Di-O-feruloyl-β-D-glucopyranoside) (=2,6-Dimethoxy-4-[(3R,4R,5S)-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-4-(hydroxymethyl)furan-3-yl]methyl]phenyl β-D-Glucopyranoside 4,6-Bis[(2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate]; **3**): Colorless powder. $[\alpha]_{\text{D}}^{27} = -11.6$ (*c* = 2.1, acetone). UV (MeOH): 224 (4.40), 232 (sh), 288 (4.10), 301 (4.03), 330 (4.10). IR (KBr): 3422, 2945, 1708, 1633, 1596, 1501, 1465. ¹H- and ¹³C-NMR: see Table 2. FAB-MS: 935 (0.5, $[M + 1]^+$), 766 (0.3), 679 (0.4), 662 (0.3), 613 (3), 515 (5), 460 (11), 420 (4), 391 (7), 307 (100), 289 (49). HR-FAB-MS: 935.3332 ($[M + 1]^+$, C₄₈H₅₅O₁₉⁺; calc. 935.3337).*

*4-O-[α-(1,2-Dihydroxyethyl)syringyl]-5,5'-dimethoxylariciresinol 4'-(4'',6''-Di-O-feruloyl-β-D-glucopyranoside) (=4-[(3R,4R,5S)-5-[4-[2,3-Dihydroxy-1-(4-hydroxy-3,5-dimethoxyphenyl)propoxy]-3,5-dimethoxyphenyl]tetrahydro-4-(hydroxymethyl)furan-3-yl]methyl]-2,6-dimethoxyphenyl β-D-Glucopyranoside 4,6-Bis[(2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate]; **4**): Colorless powder. $[\alpha]_{\text{D}}^{27} = +5.9$ (*c* = 0.9, acetone). UV (MeOH): 227 (4.44), 232 (4.01), 278 (4.12), 302 (4.05), 331 (4.11). IR (KBr): 3337, 2946, 1706, 1632, 1600, 1514, 1461. ¹H- and ¹³C-NMR: see Table 2. FAB-MS: 1161 (0.2, $[M + 1]^+$), 933 (6), 725 (0.5), 682 (0.2), 515 (10), 507 (7), 446 (9), 420 (15), 391 (20), 339 (5), 307 (100), 289 (60). HR-FAB-MS: 1161.4170 ($[M + 1]^+$, C₅₉H₆₉O₂₄⁺; calc. 1161.4178).*

REFERENCES

- [1] N. Parveen, N. U. D. Khan, *J. Indian Chem. Soc.* **1988**, *65*, 737.
- [2] S. Taniguchi, K. Yazaki, Y. U. Ryoko, K. Y. Kawakami, H. Ito, T. Hatano, T. Yoshida, *Phytochemistry* **2000**, *53*, 357.
- [3] S. C. Kuo, C. M. Teng, L. G. Chiu, T. S. Wu, S. C. Huang, J. B. Wu, T. Y. Shieh, R. J. Chang, T. C. Chou, *Planta Med.* **1991**, *57*, 247.
- [4] N. Parveen, M. P. Singh, N. U. Khan, Y. B. Achari, M. K. Logani, *Phytochemistry* **1991**, *30*, 2415.

- [5] C. K. Sung, T. Akiyama, U. Sankawa, Y. Iitaka, D. S. Han, *J. Chem. Soc., Chem. Commun.* **1980**, 19, 909.
- [6] S. El, A. El, *Planta Med.* **1996**, 14, 171.
- [7] M. Takechi, Y. Tanaka, M. Takehara, G. I. Nonaka, I. Nishioka, *Phytochemistry* **1985**, 24, 2245.
- [8] P. G. Xiao, 'Chinese Medicinal Herb Iconograph', Taiwan Business & Affairs Publishing House, Taipei, 1989, Vol. 1, p. 105.
- [9] T. H. Lee, J. L. Chiou, C. K. Lee, Y. H. Kuo, *J. Chin. Chem. Soc.* **2005**, 52, 833.
- [10] M. Sugiyama, M. Kikuchi, *Heterocycles* **1993**, 36, 117.
- [11] C. Wang, Z. Jia, *Phytochemistry* **1997**, 45, 159.
- [12] H. Otsuka, M. Takeuchi, Y. Inoshiri, T. Sato, K. Yamasaki, *Phytochemistry* **1989**, 28, 883.
- [13] M. Sugiyama, M. Kikuchi, *Chem. Pharm. Bull.* **1992**, 40, 325.
- [14] S. Hara, H. Okabe, K. Mihashi, *Chem. Pharm. Bull.* **1986**, 34, 1843.

Received November 24, 2006